Zobrazeno 1 - 10
of 29
pro vyhledávání: '"V A Chubenko"'
Autor:
M A Frolova, Ya I Kochetkova, V A Chubenko, N M Volkov, F V Moiseenko, T V Garmarnik, D M Ponomarenko, A E Orlov, Yu V Kostalanova, Yu Yu Makarycheva, A A Nizegorodzeva
Publikováno v:
Современная онкология, Vol 20, Iss 2, Pp 29-37 (2018)
The article represents case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in Russian Fe
Externí odkaz:
https://doaj.org/article/ff1e6155409e4e32bdd5d8155e1292c9
Autor:
L V Bolotina, L V Manziuk, V A Gorbunova, E I Kovalenko, G Z Mukhametshina, A I Khasanova, L Yu Vladimirova, I S Mitashok, E P Prokofyeva, I V Evstigneeva, I I Andreyashkina, N A Abramova, I L Popova, E V Karabina, A A Teterich, E A Gaysina, V A Chubenko, S V Limareva, N M Tikhanovskaya, A E Storozhakova, N Yu Samaneva, Ya V Svetitskaya, T A Snezhko, E A Kalabanova
Publikováno v:
Современная онкология, Vol 18, Iss 3, Pp 27-32 (2016)
The article shows the experience of eribulin application in actual clinical practice in Oncology institutions of the Russian Federation concerning metastatic breast cancer. We have analyzed the efficacy of the drug in case of different subtypes of th
Externí odkaz:
https://doaj.org/article/02544f99d49748aabf8218f99df2b907
Autor:
E V Artamonova, V A Gorbunova, N V Zhukov, L V Manzjuk, A G Manihas, P M Paltuev, V F Semiglazov, T Yu Semiglazova, M B Stenina, S A Tjuljandin, V A Chubenko
Publikováno v:
Современная онкология, Vol 16, Iss 2, Pp 12-16 (2014)
The leading oncologists' meeting was held on February 7, 2014 in Moscow. Those in attendance discussed treatment approaches ofbreast cancer, and in particular, locally-advanced and metastatic breast cancer. Participants came to the conclusion that pa
Externí odkaz:
https://doaj.org/article/8d8314f2d766496e8a66aea101011950
Autor:
F V Moiseenko, E N Imyanitov, D E Matsko, I I Semenov, E V Levchenko, V M Moiseenko, C A Protsenko, V A Chubenko, N V Brezhnev, A G Ievleva, A O Ivantsov, N Kh Abduloeva
Publikováno v:
Современная онкология, Vol 13, Iss 3, Pp 50-54 (2011)
Externí odkaz:
https://doaj.org/article/3d84af2730a941a4a75f0572be620c9d
Autor:
A. A. Rumyantsev, A. E. Protasova, M. Yu. Sheremet, A. Yu. Goryainova, M. V. Volkonskiy, A. G. Kedrova, S. V. Kuzmicheva, O. N. Aymamedova, Kh. S. Musaeva, S. M. Soroka, O. V. Romanchuk, V. N. Orlova, N. G. Graft, M. R. Ibragimova, Yu. I. Merzlikina, L. V. Stepura, L. B. Tatulova, A. A. Abasova, A. A. Akopyan, E. V. Arsenyeva, Yu. V. Vasilyeva, A. V. Belonogov, L. V. Krivolapova, A. A. Bobryshev, D. Yu. Vovk, I. A. Luev, N. R. Abidova, R. S. Zhikhorev, T. A. Zhelezkova, T. T. Grigoryan, T. A. Makarkina, V. A. Ekimov, A. V. Zhizhina, E. V. Karabina, O. A. Kuchevskaya, V. M. Filippova, T. A. Linchenko, A. A. Lisaeva, A. N. Fedorova, K. S. Maystrenko, E. V. Markizova, E. V. Kogay, E. P. Krasnorutskaya, M. E. Popova, Yu. Yu. Pchelin, R. A. Ryanzhina, D. B. Sidorov, E. B. Shakhnovich, S. M. Alekseev, M. V. Zinkevich, I. O. Belogortsev, V. A. Chubenko, V. M. Moiseenko, N. Kh. Abduloeva, A. A. Lebedinets, L. V. Strakh, L. K. Semenov, M. B. Bolieva, F. Z. Aydaeva
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 4, Pp 104-113 (2024)
Aim. To assess the efficacy and safety of lenvatinib and pembrolizumab for the treatment of mismatch repair-proficient endometrial cancer (EC) in routine clinical practice in Russia.Materials and methods. This multicenter, retrospective, cohort study
Externí odkaz:
https://doaj.org/article/b505b127d35446839d80501e03b80b14
Autor:
D. I. Yudin, K. K. Laktionov, F. V. Moiseenko, D. M. Ponomarenko, E. A. Chekh, V. A. Chubenko, N. V. Levchenko, V. V. Kozlov, E. О. Stepanova, K. A. Sarantseva, E. S. Denisova, M. S. Ardzinba, D. Yu. Yukalchuk
Publikováno v:
Meditsinskiy sovet = Medical Council. :12-20
Introduction. The addition of durvalumab after chemoradiation therapy in unresectable stage III non-small-cell lung cancer (NSLC) is a new standard of care.Aim. Study the features and outcomes of durvalumab maintenance treatment after chemoradiothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eaabd0a800f6de3920fc40ebad67cb01
https://doi.org/10.21518/2079-701x-2022-16-22-12-20
https://doi.org/10.21518/2079-701x-2022-16-22-12-20
Autor:
M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, G. Z. Mukhametshina, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, O. V. Sekhina, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, M. A. Lyadova, A. A. Tryakin, S. A. Tyulandin
Publikováno v:
Pelvic Surgery and Oncology. 11:11-17
Objective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic colon cancer.Materials and methods. we performed a retrospective analysis of data on patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6681ea75e504f288feb8cceb6bcda00e
https://doi.org/10.17650/2686-9594-2021-11-3-4-11-17
https://doi.org/10.17650/2686-9594-2021-11-3-4-11-17
Autor:
M. Yu. Fedyanin, F. V. Moiseenko, M. A. Lyadova, V. N. Vorobyeva, V. V. Petkau, A. V. Fateeva, E. S. Kuzmina, O. Yu. Novikova, V. A. Chubenko, N. Kh. Abduloeva, A. A. Kudryavtsev, E. O. Ignatova, R. R. Shakirov, O. A. Pardabekova, L. V. Kindyalova, S. P. Pelikh, O. A. Gladkov, S. A. Tjulandin, A. A. Tryakin
Publikováno v:
Тазовая хирургия и онкология, Vol 11, Iss 1, Pp 11-20 (2021)
Objective: to compare the efficacy and tolerability of second‑line chemotherapy with original bevacizumab (Avastin) and biosimilar bevacizumab produced by “Biocad” (Avegra) in patients with metastatic colon cancer.Materials and methods. This re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07ae5798d4267b2a431ab55c57b988d2
https://ok.abvpress.ru/jour/article/view/491
https://ok.abvpress.ru/jour/article/view/491
Autor:
M. Yu. Fedyanin, F. V. Moiseenko, D. A. Chekini, V. A. Chubenko, A. S. Zhabina, L. A. Zagorskaya, M. M. Kramchaninov, S. A. Tjulandin, V. M. Moiseyenko
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 47-52 (2020)
Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimidines,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb872f586924f0248ee41278a707359a
https://doi.org/10.21518/2079-701x-2020-20-47-52
https://doi.org/10.21518/2079-701x-2020-20-47-52
